Last 12 months
Inside the activity.
0 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2022 Filed Aug 9, 2022 20:38 UTC |
Shawver LauraDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 78,740 | $1.27 | $99,999.80 |
DisclosureSEC source: 0001209191-22-045023 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 19:39 UTC |
Koehler MariaDirector
|
GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001209191-22-036475 · doc4.xml · derivative · entry 1 Koehler Maria · CIK 0001815378 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:52 UTC |
Thompson Peter A.Director · 10% owner
|
GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001209191-22-036485 · doc4.xml · derivative · entry 1 Thompson Peter A. · CIK 0001357522 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. F2 · ownership.direct: Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:33 UTC |
Islam SaqibDirector
|
GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001209191-22-036474 · doc4.xml · derivative · entry 1 Islam Saqib · CIK 0001575408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:48 UTC |
ROOT JONATHAN DDirector
|
GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001209191-22-036478 · doc4.xml · derivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:44 UTC |
Powell Andrew Kenneth WilliamDirector
|
GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001209191-22-036476 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:31 UTC |
HERSHBERG ROBERTDirector
|
GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001209191-22-036472 · doc4.xml · derivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:27 UTC |
CAPPS VICKIE LDirector
|
GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001209191-22-036471 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:19 UTC |
Shawver LauraDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 136,214 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-22-027168 · doc4.xml · derivative · entry 2 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,214 Underlying: Common Stock · 136,214 shares Expires 2032-05-01 F2 · derivative.exercise_date: The shares subject to the option will vest on May 2, 2023. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:19 UTC |
Shawver LauraDirector · Chief Executive Officer
|
GrantCommon Stock | 68,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-027168 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,502 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:16 UTC |
Piazza JonathanChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 87,383 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-22-027162 · doc4.xml · derivative · entry 2 Piazza Jonathan · CIK 0001831967 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,383 Underlying: Common Stock · 87,383 shares Expires 2032-05-01 F2 · derivative.exercise_date: The shares subject to the option will vest on May 2, 2023. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:16 UTC |
Piazza JonathanChief Financial Officer
|
GrantCommon Stock | 43,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-027162 · doc4.xml · nonDerivative · entry 1 Piazza Jonathan · CIK 0001831967 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,225 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:12 UTC |
Odegard ValeriePresident and CSO
|
GrantStock Option (right to buy) · Derivative | 90,467 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-22-027158 · doc4.xml · derivative · entry 2 Odegard Valerie · CIK 0001832432 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,467 Underlying: Common Stock · 90,467 shares Expires 2032-05-01 F2 · derivative.exercise_date: The shares subject to the option will vest on May 2, 2023. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:12 UTC |
Odegard ValeriePresident and CSO
|
GrantCommon Stock | 45,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-027158 · doc4.xml · nonDerivative · entry 1 Odegard Valerie · CIK 0001832432 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,639 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC |
Hunder NaomiChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 86,355 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-22-027153 · doc4.xml · derivative · entry 2 Hunder Naomi · CIK 0001832170 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,355 Underlying: Common Stock · 86,355 shares Expires 2032-05-01 F2 · derivative.exercise_date: The shares subject to the option will vest on May 2, 2023. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:07 UTC |
Hunder NaomiChief Medical Officer
|
GrantCommon Stock | 43,177 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-027153 · doc4.xml · nonDerivative · entry 1 Hunder Naomi · CIK 0001832170 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,427 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:00 UTC |
Hawkinson RussSr. Vice President of Finance
|
GrantStock Option (right to buy) · Derivative | 56,670 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-22-027144 · doc4.xml · derivative · entry 2 Hawkinson Russ · CIK 0001831807 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,670 Underlying: Common Stock · 56,670 shares Expires 2032-05-01 F2 · derivative.exercise_date: The shares subject to the option will vest on May 2, 2023. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:00 UTC |
Hawkinson RussSr. Vice President of Finance
|
GrantCommon Stock | 28,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-027144 · doc4.xml · nonDerivative · entry 1 Hawkinson Russ · CIK 0001831807 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,251 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:22 UTC |
Hawkinson RussSr. Vice President of Finance
|
GrantStock Option (right to buy) · Derivative | 28,500 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006444 · doc4.xml · derivative · entry 3 Hawkinson Russ · CIK 0001831807 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2032-01-31 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:22 UTC |
Hawkinson RussSr. Vice President of Finance
|
GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006444 · doc4.xml · derivative · entry 2 Hawkinson Russ · CIK 0001831807 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-01-31 F3 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:22 UTC |
Hawkinson RussSr. Vice President of Finance
|
GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006444 · doc4.xml · nonDerivative · entry 1 Hawkinson Russ · CIK 0001831807 · Sr. Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,954 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 1,216 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2021. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:19 UTC |
Piazza JonathanChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 42,750 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006437 · doc4.xml · derivative · entry 3 Piazza Jonathan · CIK 0001831967 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,750 Underlying: Common Stock · 42,750 shares Expires 2032-01-31 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:19 UTC |
Piazza JonathanChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006437 · doc4.xml · derivative · entry 2 Piazza Jonathan · CIK 0001831967 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2032-01-31 F3 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:19 UTC |
Piazza JonathanChief Financial Officer
|
GrantCommon Stock | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006437 · doc4.xml · nonDerivative · entry 1 Piazza Jonathan · CIK 0001831967 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,534 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 2,054 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2021 and 326 shares acquired under the ESPP on December 31, 2021. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:18 UTC |
Hunder NaomiChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 42,750 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006436 · doc4.xml · derivative · entry 3 Hunder Naomi · CIK 0001832170 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,750 Underlying: Common Stock · 42,750 shares Expires 2032-01-31 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:18 UTC |
Hunder NaomiChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006436 · doc4.xml · derivative · entry 2 Hunder Naomi · CIK 0001832170 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2032-01-31 F2 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:18 UTC |
Hunder NaomiChief Medical Officer
|
GrantCommon Stock | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006436 · doc4.xml · nonDerivative · entry 1 Hunder Naomi · CIK 0001832170 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:17 UTC |
Shawver LauraDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 104,500 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006435 · doc4.xml · derivative · entry 3 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,500 Underlying: Common Stock · 104,500 shares Expires 2032-01-31 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:17 UTC |
Shawver LauraDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 165,000 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006435 · doc4.xml · derivative · entry 2 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2032-01-31 F3 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:17 UTC |
Shawver LauraDirector · Chief Executive Officer
|
GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006435 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,395 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 682 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2021. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:16 UTC |
Odegard ValeriePresident and CSO
|
GrantStock Option (right to buy) · Derivative | 49,875 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006434 · doc4.xml · derivative · entry 3 Odegard Valerie · CIK 0001832432 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,875 Underlying: Common Stock · 49,875 shares Expires 2032-01-31 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:16 UTC |
Odegard ValeriePresident and CSO
|
GrantStock Option (right to buy) · Derivative | 98,438 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001209191-22-006434 · doc4.xml · derivative · entry 2 Odegard Valerie · CIK 0001832432 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,438 Underlying: Common Stock · 98,438 shares Expires 2032-01-31 F2 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:16 UTC |
Odegard ValeriePresident and CSO
|
GrantCommon Stock | 16,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006434 · doc4.xml · nonDerivative · entry 1 Odegard Valerie · CIK 0001832432 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,406 F1 · shares: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 19:56 UTC |
ROOT JONATHAN DDirector
|
OtherCommon Stock | 105,012 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-012894 · form4.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP XII-A Disclosed balance after: 0 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners XII, L.P. ("USVP XII") and by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners XII, L.P. ("USVP XII") and by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"), without additional consideration, to its partners. F2 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 19:56 UTC |
ROOT JONATHAN DDirector
|
OtherCommon Stock | 2,069,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-012894 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP XII Disclosed balance after: 0 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners XII, L.P. ("USVP XII") and by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners XII, L.P. ("USVP XII") and by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"), without additional consideration, to its partners. F2 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| November 15, 2021 Filed Mar 18, 2022 21:14 UTC |
ROOT JONATHAN DDirector
|
PurchaseCommon Stock | 2,014 | $8.85 | $17,823.90 |
DisclosureSEC source: 0001062993-22-008141 · form4.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Spouse Disclosed balance after: 2,364 F1 · shares: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. F1 · balance_after: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. F1 · ownership.direct: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. F1 · ownership.nature: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. Read SEC document |
| June 04, 2021 Filed Sep 21, 2021 21:14 UTC |
Thompson Peter A.Director · 10% owner
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.83 | $0.00 |
DisclosureSEC source: 0001209191-21-057067 · doc4.xml · derivative · entry 1 Thompson Peter A. · CIK 0001357522 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 4, 2022 or the date of the 2022 annual meeting of the Issuer's stockholders which date has not been set by the Issuer's Board of Directors. F2 · ownership.direct: The Reporting Person is the designated representative of OrbiMed Advisors LLC ("OrbiMed Advisors") on the Issuer's Board of Directors. The reportable securities are owned indirectly by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 04, 2021 Filed Sep 21, 2021 21:10 UTC |
ROOT JONATHAN DDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.83 | $0.00 |
DisclosureSEC source: 0001209191-21-057062 · doc4.xml · derivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 4, 2022 or the date of the 2022 annual meeting of the Issuer's stockholders which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 04, 2021 Filed Sep 21, 2021 21:08 UTC |
Powell Andrew Kenneth WilliamDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.83 | $0.00 |
DisclosureSEC source: 0001209191-21-057061 · doc4.xml · derivative · entry 1 Powell Andrew Kenneth William · CIK 0001304113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 4, 2022 or the date of the 2022 annual meeting of the Issuer's stockholders which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 04, 2021 Filed Sep 21, 2021 21:06 UTC |
Islam SaqibDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.83 | $0.00 |
DisclosureSEC source: 0001209191-21-057058 · doc4.xml · derivative · entry 1 Islam Saqib · CIK 0001575408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 4, 2022 or the date of the 2022 annual meeting of the Issuer's stockholders which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 04, 2021 Filed Sep 21, 2021 21:04 UTC |
HERSHBERG ROBERTDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.83 | $0.00 |
DisclosureSEC source: 0001209191-21-057057 · doc4.xml · derivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 4, 2022 or the date of the 2022 annual meeting of the Issuer's stockholders which date has not been set by the Issuer's Board of Directors. Read SEC document |
| June 04, 2021 Filed Sep 21, 2021 21:03 UTC |
CAPPS VICKIE LDirector
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.83 | $0.00 |
DisclosureSEC source: 0001209191-21-057055 · doc4.xml · derivative · entry 1 CAPPS VICKIE L · CIK 0001248190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares subject to the option vest on the earlier of June 4, 2022 or the date of the 2022 annual meeting of the Issuer's stockholders which date has not been set by the Issuer's Board of Directors. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 15:09 UTC |
Koehler MariaDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $55.51 | $0.00 |
DisclosureSEC source: 0001209191-21-020742 · doc4.xml · derivative · entry 1 Koehler Maria · CIK 0001815378 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over the 36 months following March 12, 2021. Read SEC document |
| March 03, 2021 Filed Mar 18, 2022 21:14 UTC |
ROOT JONATHAN DDirector
|
PurchaseCommon Stock | 350 | $52.07 | $18,224.50 |
DisclosureSEC source: 0001062993-22-008141 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Spouse Disclosed balance after: 350 F1 · shares: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. F1 · balance_after: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. F1 · ownership.direct: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. F1 · ownership.nature: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:41 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
ORBIMED CAPITAL LLCDirector · 10% owner
|
ConversionSeries C Preferred Stock · Derivative | 3,918,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062387 · doc4.xml · derivative · entry 9 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments VI, LP Disclosed balance after: 0 Underlying: Common Stock · 1,055,287 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F4 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F4 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI. F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, and OrbiMed Capital LLC ("OrbiMed Capital"). Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:41 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
ORBIMED CAPITAL LLCDirector · 10% owner
|
ConversionSeries B Preferred Stock · Derivative | 9,259,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062387 · doc4.xml · derivative · entry 8 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments VI, LP Disclosed balance after: 0 Underlying: Common Stock · 2,493,741 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F4 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F4 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI. F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, and OrbiMed Capital LLC ("OrbiMed Capital"). Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:41 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
ORBIMED CAPITAL LLCDirector · 10% owner
|
ConversionSeries A Preferred Stock · Derivative | 12,857,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062387 · doc4.xml · derivative · entry 7 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments VI, LP Disclosed balance after: 0 Underlying: Common Stock · 3,462,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F4 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F4 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI. F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, and OrbiMed Capital LLC ("OrbiMed Capital"). Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:41 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
ORBIMED CAPITAL LLCDirector · 10% owner
|
PurchaseCommon Stock | 952,377 | $21.00 | $19,999,917.00 |
DisclosureSEC source: 0001209191-20-062387 · doc4.xml · nonDerivative · entry 5 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Partners Master Fund Limited Disclosed balance after: 952,377 F1 · kind: The shares were purchased in the Issuer's initial public offering. F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, and OrbiMed Capital LLC ("OrbiMed Capital"). Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. F5 · ownership.nature: These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares held by OPM. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:41 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
ORBIMED CAPITAL LLCDirector · 10% owner
|
ConversionCommon Stock | 1,055,287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-062387 · doc4.xml · nonDerivative · entry 4 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments VI, LP Disclosed balance after: 7,519,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F4 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI. F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, and OrbiMed Capital LLC ("OrbiMed Capital"). Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:41 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VI LLCDirector · 10% owner
ORBIMED CAPITAL LLCDirector · 10% owner
|
ConversionCommon Stock | 2,493,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-062387 · doc4.xml · nonDerivative · entry 3 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner ORBIMED CAPITAL LLC · CIK 0001157524 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By OrbiMed Private Investments VI, LP Disclosed balance after: 6,463,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F4 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner to OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI. Both GP VI and OrbiMed Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be beneficial owners of the shares held by OPI VI. OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPI VI. F3 · ownership.nature: This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, and OrbiMed Capital LLC ("OrbiMed Capital"). Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.